Merck asks FDA to authorize antiviral Covid pill for emergency use
Merck said it asked the FDA to authorize emergency use of its experimental antiviral pill to treat mild to moderate Covid-19 in adults at October 11, 2021 6:00 am ET
- Phase three clinical trial data showed that the drug – known as molnupiravir – reduced the chances that patients newly diagnosed with Covid would be hospitalized by about 50%.
- The experimental drug could be available to Americans by late this year.
- For more information, kindly refer to https://www.merck.com/news/merck-and-ridgeback-announce-submission-of-emergency-use-authorization-application-to-the-u-s-fda-for-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-c/
We supply Molnupiravir API and its starting material Cytidine and Uridine, if you're interested in them, kindly contact us at email@example.com.